Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Point Prevalence Survey of Palliative Care Needs in Hospitals and Residential Care Facilities for the Elderly.

NCT07313748 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-11-01
Last updated
2026-01-02

Condition(s) studied

Palliative Care, Health Services

Study summary

The goal of this observational, point-prevalence study is to assess the burden of palliative care needs among adults hospitalised in Internal Medicine and Geriatrics wards, and among residents of long-term care facilities, on the National Palliative Care Day (11 November). The main question it aims to answer is: What is the prevalence of unmet palliative care needs in hospital and long-term care settings on 11 November? Participants (patients and residents) will be evaluated through a structured, web-based questionnaire designed for this study. The survey will collect clinical, functional, and symptom-related data- including comorbidities, mobility, nutritional status, dysphagia, pressure ulcers, indicators of palliative care needs (NECPAL), pain assessment, and delirium screening (4AT)-to produce a detailed snapshot of palliative care needs across settings.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥ 18 years * Admitted to participating Internal Medicine or Geriatrics wards or resident in participating long-term care facilities for older adults (medicalised nursing homes: RSA Medicalizzata, R2, R2D, R3) on 11 November (National Palliative Care Day) * Able to provide: written informed consent for study participation and data processing, or oral consent supported by a relative/caregiver/legal proxy Exclusion Criteria: \- Inability to provide written informed consent and absence of a relative/caregiver/legal proxy able to support oral consent for participation and data processing

Primary outcome measure(s)

  • Prevalence — 1 DAY
    Prevalence of palliative care needs

Trial sites (2)

FacilityCityRegionStatus
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Roma Rome
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Roma Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07313748 on ClinicalTrials.gov ↗ ← All trials in Italy